Canaccord analyst Whitney Ijem raised the firm’s price target on Arcturus Therapeutics to $87 from $81 and keeps a Buy rating on the shares. The firm said its 4Q23 earnings report was generally inline with our expectations and w its solid cash position and near-term revenue and near-term rare disease catalysts continue to position the company uniquely well.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARCT:
- Arcturus Therapeutics price target raised to $58 from $45 at Wells Fargo
- Arcturus Therapeutics reports Q4 EPS (32c), consensus (99c)
- ARCT Earnings this Week: How Will it Perform?
- Options Volatility and Implied Earnings Moves This Week, March 04 – March 07, 2024
- EC grants ‘orphan medicinal product designation’ to Arcturus’ ARCT-032 for CF